上皮成長因子受容体（EGFR）阻害剤の世界市場 2024-2028

上皮成長因子受容体（EGFR）阻害剤市場は、2023-2028年に67億5,000万米ドル、予測期間中のCAGRは8.6％で成長すると予測されます。

当レポートでは、上皮成長因子受容体（EGFR）阻害剤市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25社のベンダーを網羅したベンダー分析などを掲載しています。

当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、主要ながん適応症の有病率の上昇、個別化医療の認知度の上昇と導入、技術進歩と研究の進展によって牽引されています。

当レポートでは、今後数年間における上皮成長因子受容体（EGFR）阻害剤市場の成長を促進する主な要因の一つとして、各種がんの治療に関する研究領域の拡大を挙げています。また、医薬品パイプラインの拡大や償還プログラムの増加が、市場の大きな需要につながります。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場セグメント分析
• 市場規模 2023
• 市場の見通し 2023-2028

第4章 市場規模実績

• 世界の上皮成長因子受容体（EGFR）阻害剤市場 2018-2022
• 流通チャネル別セグメント分析 2018-2022
• 適応症別セグメント分析 2018-2022
• 地域別セグメント分析 2018-2022
• 国別セグメント分析 2018-2022

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション：流通チャネル別

• 市場セグメント
• 比較：流通チャネル別
• 小売薬局：市場規模と予測 2023-2028
• 病院薬局：市場規模と予測 2023-2028
• オンライン薬局：市場規模と予測 2023-2028
• 市場機会：流通チャネル別

第7章 市場セグメンテーション：適応症別

• 市場セグメント
• 比較適応症別
• 肺がん：市場規模と予測 2023-2028
• 結腸直腸がん：市場規模と予測 2023-2028
• 乳がん：市場規模と予測 2023-2028
• その他：市場規模と予測 2023-2028
• 市場機会：適応症別

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米：市場規模と予測 2023-2028
• 欧州：市場規模と予測 2023-2028
• アジア：市場規模と予測 2023-2028
• 世界のその他の地域：市場規模と予測 2023-2028
• 米国：市場規模と予測 2023-2028
• ドイツ：市場規模と予測 2023-2028
• 英国：市場規模と予測 2023-2028
• 中国：市場規模と予測 2023-2028
• カナダ：市場規模と予測 2023-2028
• 市場機会：地域別

第10章 促進要因・課題・動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• Amgen Inc.
• Apollomics Inc.
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Co.
• Checkpoint Therapeutics Inc.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Johnson and Johnson
• Novartis AG
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Puma Biotechnology Inc.
• Takeda Pharmaceutical Co. Ltd.

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibits6: Executive Summary - Chart on Market Segmentation by Indication
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits18: Historic Market Size - Data Table on global epidermal growth factor receptor (egfr) inhibitors market 2018 - 2022 ($ million)
• Exhibits19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
• Exhibits20: Historic Market Size - Indication Segment 2018 - 2022 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2023 and 2028
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
• Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
• Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
• Exhibits29: Chart on Market condition - Five forces 2023 and 2028
• Exhibits30: Chart on Distribution Channel - Market share 2023-2028 (%)
• Exhibits31: Data Table on Distribution Channel - Market share 2023-2028 (%)
• Exhibits32: Chart on Comparison by Distribution Channel
• Exhibits33: Data Table on Comparison by Distribution Channel
• Exhibits34: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibits35: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibits36: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibits37: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibits38: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibits39: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibits40: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibits41: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibits42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibits43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibits44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibits45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibits46: Market opportunity by Distribution Channel ($ million)
• Exhibits47: Data Table on Market opportunity by Distribution Channel ($ million)
• Exhibits48: Chart on Indication - Market share 2023-2028 (%)
• Exhibits49: Data Table on Indication - Market share 2023-2028 (%)
• Exhibits50: Chart on Comparison by Indication
• Exhibits51: Data Table on Comparison by Indication
• Exhibits52: Chart on Lung cancer - Market size and forecast 2023-2028 ($ million)
• Exhibits53: Data Table on Lung cancer - Market size and forecast 2023-2028 ($ million)
• Exhibits54: Chart on Lung cancer - Year-over-year growth 2023-2028 (%)
• Exhibits55: Data Table on Lung cancer - Year-over-year growth 2023-2028 (%)
• Exhibits56: Chart on Colorectal cancer - Market size and forecast 2023-2028 ($ million)
• Exhibits57: Data Table on Colorectal cancer - Market size and forecast 2023-2028 ($ million)
• Exhibits58: Chart on Colorectal cancer - Year-over-year growth 2023-2028 (%)
• Exhibits59: Data Table on Colorectal cancer - Year-over-year growth 2023-2028 (%)
• Exhibits60: Chart on Breast cancer - Market size and forecast 2023-2028 ($ million)
• Exhibits61: Data Table on Breast cancer - Market size and forecast 2023-2028 ($ million)
• Exhibits62: Chart on Breast cancer - Year-over-year growth 2023-2028 (%)
• Exhibits63: Data Table on Breast cancer - Year-over-year growth 2023-2028 (%)
• Exhibits64: Chart on Others - Market size and forecast 2023-2028 ($ million)
• Exhibits65: Data Table on Others - Market size and forecast 2023-2028 ($ million)
• Exhibits66: Chart on Others - Year-over-year growth 2023-2028 (%)
• Exhibits67: Data Table on Others - Year-over-year growth 2023-2028 (%)
• Exhibits68: Market opportunity by Indication ($ million)
• Exhibits69: Data Table on Market opportunity by Indication ($ million)
• Exhibits70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits71: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits73: Chart on Geographic comparison
• Exhibits74: Data Table on Geographic comparison
• Exhibits75: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits76: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits77: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibits78: Data Table on North America - Year-over-year growth 2023-2028 (%)
• Exhibits79: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits80: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits81: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits83: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits84: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits85: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits91: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibits92: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibits93: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibits94: Data Table on US - Year-over-year growth 2023-2028 (%)
• Exhibits95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits97: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits99: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibits100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibits101: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibits102: Data Table on UK - Year-over-year growth 2023-2028 (%)
• Exhibits103: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibits104: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibits105: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibits106: Data Table on China - Year-over-year growth 2023-2028 (%)
• Exhibits107: Chart on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibits108: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibits109: Chart on Canada - Year-over-year growth 2023-2028 (%)
• Exhibits110: Data Table on Canada - Year-over-year growth 2023-2028 (%)
• Exhibits111: Market opportunity By Geographical Landscape ($ million)
• Exhibits112: Data Tables on Market opportunity By Geographical Landscape ($ million)
• Exhibits113: Impact of drivers and challenges in 2023 and 2028
• Exhibits114: Overview on Criticality of inputs and Factors of differentiation
• Exhibits115: Overview on factors of disruption
• Exhibits116: Impact of key risks on business
• Exhibits117: Vendors covered
• Exhibits118: Matrix on vendor position and classification
• Exhibits119: Amgen Inc. - Overview
• Exhibits120: Amgen Inc. - Product / Service
• Exhibits121: Amgen Inc. - Key offerings
• Exhibits122: Apollomics Inc. - Overview
• Exhibits123: Apollomics Inc. - Product / Service
• Exhibits124: Apollomics Inc. - Key news
• Exhibits125: Apollomics Inc. - Key offerings
• Exhibits126: AstraZeneca Plc - Overview
• Exhibits127: AstraZeneca Plc - Product / Service
• Exhibits128: AstraZeneca Plc - Key news
• Exhibits129: AstraZeneca Plc - Key offerings
• Exhibits130: Boehringer Ingelheim International GmbH - Overview
• Exhibits131: Boehringer Ingelheim International GmbH - Business segments
• Exhibits132: Boehringer Ingelheim International GmbH - Key news
• Exhibits133: Boehringer Ingelheim International GmbH - Key offerings
• Exhibits134: Boehringer Ingelheim International GmbH - Segment focus
• Exhibits135: Bristol Myers Squibb Co. - Overview
• Exhibits136: Bristol Myers Squibb Co. - Product / Service
• Exhibits137: Bristol Myers Squibb Co. - Key news
• Exhibits138: Bristol Myers Squibb Co. - Key offerings
• Exhibits139: Checkpoint Therapeutics Inc. - Overview
• Exhibits140: Checkpoint Therapeutics Inc. - Product / Service
• Exhibits141: Checkpoint Therapeutics Inc. - Key offerings
• Exhibits142: Eli Lilly and Co. - Overview
• Exhibits143: Eli Lilly and Co. - Product / Service
• Exhibits144: Eli Lilly and Co. - Key news
• Exhibits145: Eli Lilly and Co. - Key offerings
• Exhibits146: F. Hoffmann La Roche Ltd. - Overview
• Exhibits147: F. Hoffmann La Roche Ltd. - Business segments
• Exhibits148: F. Hoffmann La Roche Ltd. - Key news
• Exhibits149: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibits150: F. Hoffmann La Roche Ltd. - Segment focus
• Exhibits151: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
• Exhibits152: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
• Exhibits153: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings
• Exhibits154: Johnson and Johnson - Overview
• Exhibits155: Johnson and Johnson - Business segments
• Exhibits156: Johnson and Johnson - Key news
• Exhibits157: Johnson and Johnson - Key offerings
• Exhibits158: Johnson and Johnson - Segment focus
• Exhibits159: Novartis AG - Overview
• Exhibits160: Novartis AG - Business segments
• Exhibits161: Novartis AG - Key offerings
• Exhibits162: Novartis AG - Segment focus
• Exhibits163: Otsuka Holdings Co. Ltd. - Overview
• Exhibits164: Otsuka Holdings Co. Ltd. - Business segments
• Exhibits165: Otsuka Holdings Co. Ltd. - Key offerings
• Exhibits166: Otsuka Holdings Co. Ltd. - Segment focus
• Exhibits167: Pfizer Inc. - Overview
• Exhibits168: Pfizer Inc. - Product / Service
• Exhibits169: Pfizer Inc. - Key news
• Exhibits170: Pfizer Inc. - Key offerings
• Exhibits171: Puma Biotechnology Inc. - Overview
• Exhibits172: Puma Biotechnology Inc. - Product / Service
• Exhibits173: Puma Biotechnology Inc. - Key offerings
• Exhibits174: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibits175: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibits176: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibits177: Takeda Pharmaceutical Co. Ltd. - Key offerings
• Exhibits178: Inclusions checklist
• Exhibits179: Exclusions checklist
• Exhibits180: Currency conversion rates for US$
• Exhibits181: Research methodology
• Exhibits182: Validation techniques employed for market sizing
• Exhibits183: Information sources
• Exhibits184: List of abbreviations

The epidermal growth factor receptor (EGFR) inhibitors market is forecasted to grow by USD 6.75 bn during 2023-2028, accelerating at a CAGR of 8.6% during the forecast period. The report on the epidermal growth factor receptor (EGFR) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rise in the prevalence of major cancer indications, increasing awareness and adoption of personalized medicine, and advancements in technology and research.

Technavio's epidermal growth factor receptor (EGFR) inhibitors market is segmented as below:

By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Online pharmacies

By Indication

• Lung cancer
• Colorectal cancer
• Breast cancer
• Others

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the increase in research areas for treatment of various types of cancer as one of the prime reasons driving the epidermal growth factor receptor (EGFR) inhibitors market growth during the next few years. Also, rise in number of drug pipelines and increasing reimbursement programs will lead to sizable demand in the market.

The report on the epidermal growth factor receptor (EGFR) inhibitors market covers the following areas:

• Epidermal growth factor receptor (EGFR) inhibitors market sizing
• Epidermal growth factor receptor (EGFR) inhibitors market forecast
• Epidermal growth factor receptor (EGFR) inhibitors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epidermal growth factor receptor (EGFR) inhibitors market vendors that include Amgen Inc., ASSERTIO HOLDINGS INC., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Checkpoint Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Hansoh Pharmaceutical Group Co. Ltd., hutchison medipharma ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Puma Biotechnology Inc., Takeda Pharmaceutical Co. Ltd., Apollomics Inc., CULLINAN ONCOLOGY INC., and Lutris Pharma. Also, the epidermal growth factor receptor (EGFR) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Indication
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global epidermal growth factor receptor (EGFR) inhibitors market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global epidermal growth factor receptor (egfr) inhibitors market 2018 - 2022 ($ million)
• 4.2 Distribution Channel Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
• 4.3 Indication Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Indication Segment 2018 - 2022 ($ million)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Distribution Channel

• 6.1 Market segments
• Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
• 6.2 Comparison by Distribution Channel
• Exhibit 32: Chart on Comparison by Distribution Channel
• Exhibit 33: Data Table on Comparison by Distribution Channel
• 6.3 Retail pharmacies - Market size and forecast 2023-2028
• Exhibit 34: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 35: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 36: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
• 6.4 Hospital pharmacies - Market size and forecast 2023-2028
• Exhibit 38: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 39: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 40: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
• 6.5 Online pharmacies - Market size and forecast 2023-2028
• Exhibit 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
• 6.6 Market opportunity by Distribution Channel
• Exhibit 46: Market opportunity by Distribution Channel ($ million)
• Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ million)

7 Market Segmentation by Indication

• 7.1 Market segments
• Exhibit 48: Chart on Indication - Market share 2023-2028 (%)
• Exhibit 49: Data Table on Indication - Market share 2023-2028 (%)
• 7.2 Comparison by Indication
• Exhibit 50: Chart on Comparison by Indication
• Exhibit 51: Data Table on Comparison by Indication
• 7.3 Lung cancer - Market size and forecast 2023-2028
• Exhibit 52: Chart on Lung cancer - Market size and forecast 2023-2028 ($ million)
• Exhibit 53: Data Table on Lung cancer - Market size and forecast 2023-2028 ($ million)
• Exhibit 54: Chart on Lung cancer - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on Lung cancer - Year-over-year growth 2023-2028 (%)
• 7.4 Colorectal cancer - Market size and forecast 2023-2028
• Exhibit 56: Chart on Colorectal cancer - Market size and forecast 2023-2028 ($ million)
• Exhibit 57: Data Table on Colorectal cancer - Market size and forecast 2023-2028 ($ million)
• Exhibit 58: Chart on Colorectal cancer - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Colorectal cancer - Year-over-year growth 2023-2028 (%)
• 7.5 Breast cancer - Market size and forecast 2023-2028
• Exhibit 60: Chart on Breast cancer - Market size and forecast 2023-2028 ($ million)
• Exhibit 61: Data Table on Breast cancer - Market size and forecast 2023-2028 ($ million)
• Exhibit 62: Chart on Breast cancer - Year-over-year growth 2023-2028 (%)
• Exhibit 63: Data Table on Breast cancer - Year-over-year growth 2023-2028 (%)
• 7.6 Others - Market size and forecast 2023-2028
• Exhibit 64: Chart on Others - Market size and forecast 2023-2028 ($ million)
• Exhibit 65: Data Table on Others - Market size and forecast 2023-2028 ($ million)
• Exhibit 66: Chart on Others - Year-over-year growth 2023-2028 (%)
• Exhibit 67: Data Table on Others - Year-over-year growth 2023-2028 (%)
• 7.7 Market opportunity by Indication
• Exhibit 68: Market opportunity by Indication ($ million)
• Exhibit 69: Data Table on Market opportunity by Indication ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 73: Chart on Geographic comparison
• Exhibit 74: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 Germany - Market size and forecast 2023-2028
• Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.9 UK - Market size and forecast 2023-2028
• Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.10 China - Market size and forecast 2023-2028
• Exhibit 103: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 104: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 105: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 106: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.11 Canada - Market size and forecast 2023-2028
• Exhibit 107: Chart on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibit 108: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibit 109: Chart on Canada - Year-over-year growth 2023-2028 (%)
• Exhibit 110: Data Table on Canada - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 111: Market opportunity By Geographical Landscape ($ million)
• Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 113: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 115: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 116: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 117: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 118: Matrix on vendor position and classification
• 12.3 Amgen Inc.
• Exhibit 119: Amgen Inc. - Overview
• Exhibit 120: Amgen Inc. - Product / Service
• Exhibit 121: Amgen Inc. - Key offerings
• 12.4 Apollomics Inc.
• Exhibit 122: Apollomics Inc. - Overview
• Exhibit 123: Apollomics Inc. - Product / Service
• Exhibit 124: Apollomics Inc. - Key news
• Exhibit 125: Apollomics Inc. - Key offerings
• 12.5 AstraZeneca Plc
• Exhibit 126: AstraZeneca Plc - Overview
• Exhibit 127: AstraZeneca Plc - Product / Service
• Exhibit 128: AstraZeneca Plc - Key news
• Exhibit 129: AstraZeneca Plc - Key offerings
• 12.6 Boehringer Ingelheim International GmbH
• Exhibit 130: Boehringer Ingelheim International GmbH - Overview
• Exhibit 131: Boehringer Ingelheim International GmbH - Business segments
• Exhibit 132: Boehringer Ingelheim International GmbH - Key news
• Exhibit 133: Boehringer Ingelheim International GmbH - Key offerings
• Exhibit 134: Boehringer Ingelheim International GmbH - Segment focus
• 12.7 Bristol Myers Squibb Co.
• Exhibit 135: Bristol Myers Squibb Co. - Overview
• Exhibit 136: Bristol Myers Squibb Co. - Product / Service
• Exhibit 137: Bristol Myers Squibb Co. - Key news
• Exhibit 138: Bristol Myers Squibb Co. - Key offerings
• 12.8 Checkpoint Therapeutics Inc.
• Exhibit 139: Checkpoint Therapeutics Inc. - Overview
• Exhibit 140: Checkpoint Therapeutics Inc. - Product / Service
• Exhibit 141: Checkpoint Therapeutics Inc. - Key offerings
• 12.9 Eli Lilly and Co.
• Exhibit 142: Eli Lilly and Co. - Overview
• Exhibit 143: Eli Lilly and Co. - Product / Service
• Exhibit 144: Eli Lilly and Co. - Key news
• Exhibit 145: Eli Lilly and Co. - Key offerings
• 12.10 F. Hoffmann La Roche Ltd.
• Exhibit 146: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 147: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 148: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 149: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 150: F. Hoffmann La Roche Ltd. - Segment focus
• 12.11 Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Exhibit 151: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
• Exhibit 152: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
• Exhibit 153: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings
• 12.12 Johnson and Johnson
• Exhibit 154: Johnson and Johnson - Overview
• Exhibit 155: Johnson and Johnson - Business segments
• Exhibit 156: Johnson and Johnson - Key news
• Exhibit 157: Johnson and Johnson - Key offerings
• Exhibit 158: Johnson and Johnson - Segment focus
• 12.13 Novartis AG
• Exhibit 159: Novartis AG - Overview
• Exhibit 160: Novartis AG - Business segments
• Exhibit 161: Novartis AG - Key offerings
• Exhibit 162: Novartis AG - Segment focus
• 12.14 Otsuka Holdings Co. Ltd.
• Exhibit 163: Otsuka Holdings Co. Ltd. - Overview
• Exhibit 164: Otsuka Holdings Co. Ltd. - Business segments
• Exhibit 165: Otsuka Holdings Co. Ltd. - Key offerings
• Exhibit 166: Otsuka Holdings Co. Ltd. - Segment focus
• 12.15 Pfizer Inc.
• Exhibit 167: Pfizer Inc. - Overview
• Exhibit 168: Pfizer Inc. - Product / Service
• Exhibit 169: Pfizer Inc. - Key news
• Exhibit 170: Pfizer Inc. - Key offerings
• 12.16 Puma Biotechnology Inc.
• Exhibit 171: Puma Biotechnology Inc. - Overview
• Exhibit 172: Puma Biotechnology Inc. - Product / Service
• Exhibit 173: Puma Biotechnology Inc. - Key offerings
• 12.17 Takeda Pharmaceutical Co. Ltd.
• Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 176: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 177: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 178: Inclusions checklist
• Exhibit 179: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 180: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 181: Research methodology
• Exhibit 182: Validation techniques employed for market sizing
• Exhibit 183: Information sources
• 13.5 List of abbreviations
• Exhibit 184: List of abbreviations